Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, minoxidil 2% solution was more effective than tacrolimus 0.1% ointment for promoting hair regrowth in mild to moderate patchy alopecia areata.

This study found no SARS-CoV-2 RNA in the semen and urine of a COVID-19 patient, suggesting possible viral clearance or absence in these fluids.

This study found that the combination of docetaxel, cisplatin, and 5-fluorouracil is active and feasible for treating squamous cell carcinoma of the head and neck, with dose level I recommended for further testing.

This review discusses the potential of organoids in modeling COVID-19 disease and developing therapies, without reporting new results, and highlights opportunities and challenges in their application for research.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

This review discusses the challenges of interpreting observational studies on COVID-19 due to biases from non-representative samples, such as collider bias, and suggests better sampling methods to mitigate these issues.

This review discusses the potential anticancer effects of medicinal plants, highlighting their diverse phytoconstituents and mechanisms, and considers both their future prospects and limitations in cancer treatment.

This review summarizes recent advances in understanding the molecular mechanisms of hair follicle formation and discusses potential future clinical applications for treating hair loss and skin tumors, but it reports no new clinical results.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

Topical treatment SM04554 safely promotes hair growth in male baldness.

In this study, the researchers observed that male pattern alopecia is characterized by miniature follicles, enlarged sebaceous glands, and an increased number of mast cells, without significant abnormalities in enzyme activity.

This study found that low fluence photoepilation with intense pulsed light targets the pigmented area of hair follicles, causing temporary hair loss by inducing a catagen-like state without severe follicle damage.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

This study suggests that minoxidil may serve as a suitable reference drug for high permeability classification in the Biopharmaceutics Classification System due to its consistent permeability across different intestinal segments and pH levels.

This study found that using 'moha: 5-in-1' hair oil for 8 weeks significantly reduced hair fall, increased hair growth rate and thickness, and decreased scalp dandruff among healthy adults with alopecia, with no adverse effects reported.

This study reported that Trichoscan, a computer-assisted hair measurement system, was not supported as accurate for clinical trials due to errors in signal detection, despite its analysis speed.

This study investigated the histopathology of ectodermal dysplasia/skin fragility syndrome, identifying specific skin and hair abnormalities associated with PKP1 gene mutations in two young female patients.

In this study, ovarian SAHA was found to be independently associated with a more insulin-resistant profile and increased risk of glucose abnormalities in women with PCOS, beyond common risk factors.

This exploratory pilot study reported that using a 2% Oleosome-FGF-2 fusion extract scalp serum twice daily for 84 days in women with telogen effluvium and brittle hair improved hair density, anagen/telogen ratio, hair shaft thickness, and scalp hydration compared to a placebo.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

This study found that Limelight (CB-EVs) exosomes significantly promoted hair elongation ex vivo without cytotoxicity, suggesting potential as a safe and effective hair growth therapy.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

The topical finasteride spray was safe and well-tolerated with stable effects.

In this study, the researchers used molecular docking to identify Erythrabyssin II from Erythrina subumbrans as a potential candidate for anti-alopecia treatment, comparable to minoxidil, suggesting clinical trials are needed to evaluate its pharmacological effects.